Trial Profile
F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction Due to Alzheimer Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2021
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Acronyms Protocol E
- 14 Jan 2021 Status changed from active, no longer recruiting to completed.
- 25 Feb 2020 Planned End Date changed from 1 Sep 2020 to 1 Jan 2021.
- 25 Feb 2020 Planned primary completion date changed from 1 May 2020 to 1 Dec 2020.